Abstract:Pancreatic ductal adenocarcinoma (PDA) is a highly lethal malignancy with a 5‐year survival rate of 6%, due in part to therapy resistance and late stage at diagnosis. A detailed understanding of the molecular alterations underlying this disease is required to uncover mechanisms of tumorigenesis and enable development of more effective therapies. We recently developed a novel 3D model system for culturing normal and diseased pancreatic tissue from both mice and humans. These pancreatic organoids can be passaged indefinitely in vitro , frozen, thawed, genetically manipulated and transplanted orthotopically into mice where they generate lesions faithfully reflecting their donor phenotype (normal, pre‐malignant, malignant). The ability to culture both normal and tumor‐derived cells in vitro under identical conditions has for the first time allowed a direct comparison of gene expression changes and response to therapeutic agents. We have used this new model to investigate tumor cell‐stroma interactions, screen drug libraries and model genetic alterations found in human tumors. G‐protein coupled receptors (GPRCs) transduce extracellular signals from a variety of ligands through the plasma membrane, resulting in the modulation of intracellular signaling pathways. This is accomplished in large measure by the activation of heterotrimeric G‐proteins and downstream second messengers. Composed of over 900 members in humans, GPCRs are seven‐transmembrane proteins that regulate many physiological processes including vision, olfaction, taste, behavior and autonomic nervous system transmission. This wide array of functions has resulted in the extensive utilization of GPCR targeted therapeutics, accounting for 30–50% of all currently used drugs. The wide use of GPCR drugs can also be attributed to GPCR localization on the cell surface, abrogating the requirement for a drug to be cell permeable, as well as the ability of GPCRs to bind a variety of ligands, including antibodies, peptides and small molecules. Furthermore, GPCR signaling can be tightly regulated through the utilization of agonists, antagonists and inverse agonists. However, drugs targeting GPCRs are rarely utilized in cancer treatment, despite evidence that GPCRs mediate many aspects of tumorigenesis, including cell proliferation, invasion, immune cell recruitment and secondary niche generation. Genomic analyses have uncovered GPCR mutations, copy number alterations and gene expression and methylation changes in a wide variety of cancers. We have utilized the organoid system to identify and characterize GPCRs upregulated in PDA. Furthermore, we have performed high throughout screens to identify GPCR‐targeted FDA approved drugs that specifically reduce proliferation in tumor‐derived organoids. As agonists and antagonists of GPCRs are currently used widely in the clinic, the identification of GPCRs as novel drivers of tumorigenesis may have immediate benefits for human cancer therapy.

The power of many: Multilevel targeting of representative chemokine and metabolite GPCRs in personalized cancer therapy

Targeting G Protein–Coupled Receptors in Immuno-Oncological Therapies

An Insight into GPCR and G-Proteins as Cancer Drivers

GPCRs: emerging targets for novel T cell immune checkpoint therapy

Pan-cancer in Silico Analysis of Somatic Mutations in G-protein Coupled Receptors: the Effect of Evolutionary Conservation and Natural Variance

Large set data mining reveals overexpressed GPCRs in prostate and breast cancer: potential for active targeting with engineered anti-cancer nanomedicines

Organoid models to interrogate GPCR regulation of pancreatic tumorigenesis

Overexpression of G Protein-Coupled Receptors in Cancer Cells: Involvement in Tumor Progression.

G protein-coupled receptor-mediated signaling of immunomodulation in tumor progression

A Novel Classifier Combining G Protein-Coupled Receptors and the Tumor Microenvironment is Associated with Survival Status in Glioblastoma.

Multi-omics integration analysis of GPCRs in pan-cancer to uncover inter-omics relationships and potential driver genes.

The Advancement of Pathway on G Protein-coupled Receptors(GPCRs) Target to Cancer

Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy

Recent Advances of Small Molecular Regulators Targeting G Protein- Coupled Receptors Family for Oncology Immunotherapy.

GPCRs in pancreatic adenocarcinoma: Contributors to tumour biology and novel therapeutic targets

Targeting cytokine and chemokine signaling pathways for cancer therapy

Shifting the paradigm: engaging multicellular networks for cancer therapy

G Protein‐Coupled receptors and heterotrimeric G proteins as cancer drivers

gC1qR: A New Target for Cancer Immunotherapy

The Role of Chemoattractant Receptors in Shaping the Tumor Microenvironment

Advance in the role of chemokines/chemokine receptors in carcinogenesis: Focus on pancreatic cancer